Champions Oncology, Inc. — FY2013 Form 10-K Summary
Reporting period: Fiscal year ended April 30, 2013; the filing compares FY2013 with FY2012. This is an annual report, not a report limited to calendar-year 2012 or fiscal Q4. The company develops and sells TumorGraft-based oncology services through Personalized Oncology Solutions (POS) for patients and physicians, and Translational Oncology Solutions (TOS) for pharmaceutical and biotechnology customers.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $8.323 million | $7.149 million |
| POS revenue | $2.390 million | $2.332 million |
| TOS revenue | $5.933 million | $4.817 million |
| Operating loss | $6.221 million | $9.065 million |
| Net loss | $6.330 million | $8.661 million |
| Net loss per share | $0.12 | $0.19 |
| Cash used in operating activities | $4.292 million | $5.227 million |
| Cash and cash equivalents at year-end | $9.561 million | $4.754 million |
- Revenue increased 16.4%. TOS revenue rose 23.2%; POS revenue grew 2.5%, as increased patient volume was offset by lower pricing.
- Cost of POS and TOS services totaled $5.328 million, implying consolidated gross profit of approximately $2.995 million and gross margin of approximately 36% (calculated from reported figures). POS gross margin was negative 12%, down from 1%; TOS gross margin was 55%, up from 47%, partly reflecting a one-time Cephalon payment.
- Total costs and operating expenses fell 10.3% to $14.544 million. R&D expense declined 34.6% to $1.920 million; sales and marketing fell 9.0% to $2.665 million; general and administrative fell 15.0% to $4.631 million.
- Working capital was $7.5 million. Current assets were $10.376 million and current liabilities $2.929 million. The filing reports no off-balance-sheet debt or similar obligations; it does report a $1.046 million warrant liability. No conventional borrowing balance is identified in the provided financial statements.
- Financing activities provided $9.141 million, primarily from a January 2013 private placement that raised $9.3 million gross. Redeemable common stock was classified as temporary equity because investors have conditional cash put rights tied to specified transactions.
Material changes and unusual items
- The company moved laboratory work in-house from a contract research organization, increased laboratory staffing and infrastructure, and continued lower POS pricing intended to increase patient volume and expand its TumorBank. POS implants increased 58% to 152; patients with completed studies increased 168% to 51.
- Cephalon paid $880,000 in December 2012 in exchange for relinquishing future milestones and royalties on one compound; the amount was recognized as revenue. A second compound remained under evaluation. The agreement also generated $617,000 of other revenue in FY2013 from work performed, in addition to the buyout payment.
- The financing issued 18.6 million common shares at $0.50 per share and warrants for 1.86 million additional shares at a $0.66 exercise price. Anti-dilution provisions also resulted in 1,064,658 additional shares for investors in the 2011 placement. Warrants with exercise-price reset provisions are recorded as liabilities and remeasured through earnings.
- Warrant fair-value changes produced $74,000 of expense in FY2013, compared with $417,000 of income in FY2012; these noncash changes do not affect cash balances.
Outlook, risks and contingencies
- Management said year-end cash was adequate to fund operations at least through fiscal 2014, while acknowledging that additional capital may be needed and could be unavailable on acceptable terms. No formal revenue or earnings guidance is provided.
- The company expected operating losses to continue until revenue grows enough to cover costs. POS profitability is a key concern: prices were reduced, POS gross margin turned negative, TumorGraft growth and testing can take more than six months, and not all implants succeed. Evidence linking mouse-study results to patient outcomes was described as limited.
- Principal risks include dependence on a single Baltimore laboratory and live-mouse colonies; potential additional FDA regulation of laboratory-developed tests; state laboratory licensing and other healthcare regulation; intense competition; unpatented core TumorGraft technology and broader intellectual-property risks; ability to retain key staff and commercialize services; and ongoing funding needs.
- Conditional investor put rights could require cash redemption at $0.50 or $0.75 per share upon specified change-of-control or asset-sale events, subject to termination conditions. Registration-rights penalties are possible, but management said they were not probable and no accrual was recorded.
- Management reported effective disclosure controls and internal control over financial reporting. The independent auditor issued an unqualified opinion on the financial statements but did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether POS volume growth can improve unit economics and restore positive gross margins despite reduced pricing.
- How much TOS revenue and margin growth is recurring, excluding the $880,000 Cephalon buyout and other agreement-specific work.
- Cash burn, working-capital needs, and the basis for management’s estimate that cash would fund operations through at least fiscal 2014.
- Potential dilution and cash exposure from outstanding options and warrants, reset provisions, redeemable shares, and conditional put rights.
- Progress in validating TumorGraft results against patient outcomes, and any regulatory developments affecting laboratory-developed tests.